{"DataElement":{"publicId":"2431622","version":"1","preferredName":"Radical Prostatectomy Gleason Histopathologic Grade Tertiary Pattern Integer","preferredDefinition":"An integer representing the third most predominant Gleason pattern or grade present in an invasive prostate carcinoma. A teritary pattern can only be assigned in a radical prostatectomy specimen, and is not required.","longName":"2431415v1.0:2433968v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2431415","version":"1","preferredName":"Radical Prostatectomy Gleason Grade for Prostate Cancer Tertiary Gleason Score for Prostate Cancer","preferredDefinition":"Surgery to remove the entire prostate. The two types of radical prostatectomy are retropubic prostatectomy and perineal prostatectomy.:definition pending_definition pending","longName":"2431310v1.0:2431266v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2431310","version":"1","preferredName":"Radical Prostatectomy Gleason Grade for Prostate Cancer","preferredDefinition":"Surgery to remove the entire prostate. The two types of radical prostatectomy are retropubic prostatectomy and perineal prostatectomy.:definition pending","longName":"C15399:C28107","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radical Prostatectomy","conceptCode":"C15399","definition":"The surgical removal of all of the prostate as well as some surrounding tissue, including lymph nodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Gleason Grading System","conceptCode":"C28107","definition":"A grading system for prostatic carcinoma based on the microscopic glandular architectural patterns of the malignant epithelial cells. Nuclear atypia is not evaluated. It defines five patterns or grades which reflect decreasing differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCF721-F36E-3D10-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2431266","version":"1","preferredName":"Tertiary Gleason Score for Prostate Cancer","preferredDefinition":"definition pending","longName":"C48605","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tertiary Gleason Pattern","conceptCode":"C48605","definition":"Prostate carcinoma patterns occupying less than 5% of the tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCEA00-2431-36A2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2222502","version":"1","preferredName":"UML DEFAULT CD","preferredDefinition":"Default Conceptual Domain for UML Loader","longName":"UML DEFAULT CD","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5E53F3B-47A4-52D1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-04-29","modifiedBy":"DWARZEL","dateModified":"2021-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CAP PROTOCOLS:College of American Pathologists Cancer Protocols","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DE1123-1A57-46AC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"04/01/14 jc released UMLLOADER_CAP content per R. Crowley.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2433968","version":"1","preferredName":"Gleason Score for Prostate Cancer Integer","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable._The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable._A number with no fractional part.","longName":"2433968v1.0","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":"1","maxValue":"5","decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2183782","version":"1","preferredName":"NCIP","preferredDefinition":"Cancer Biomedical Informatics Grid","longName":"NCIP","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DACB2549-3BE3-73F7-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2434122","version":"1","preferredName":"Gleason Score Integer","preferredDefinition":"A system of grading prostate cancer cells to determine the best treatment and to predict how well a person is likely to do. A low Gleason score means the cancer cells are very similar to normal prostate cells; a high Gleason score means the cancer cells are very different from normal. :A number with no fractional part.","longName":"C28084:C45255","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-D037-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CAP PROTOCOLS:College of American Pathologists Cancer Protocols","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-CEDA-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2005-11-28","modifiedBy":"CURTIST","dateModified":"2010-09-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2857187","version":"1","longName":"CAP Cancer Checklists","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812068","version":"1","longName":"edu.upmc.opi.cabig.caties.cap.domain.prostate.radical_prostatectomy","context":"NCIP"}]}],"AlternateNames":[{"name":"edu.upmc.opi.cabig.caties.cap.domain.prostate.radical_prostatectomy.RadicalProstatectomyGleasonHistopathologicGrade.tertiaryPattern","type":"UML Qualified Attr","context":"NCIP"},{"name":"RadicalProstatectomyGleasonHistopathologicGrade:tertiaryPattern","type":"UML Class:UML Attr","context":"NCIP"}],"ReferenceDocuments":[{"name":"Tertiary Pattern","type":"Preferred Question Text","description":"Tertiary Pattern","url":null,"context":"NCIP"}],"origin":"CAP PROTOCOLS:College of American Pathologists Cancer Protocols","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DD8B8C-7886-686E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"CHILLIJ","dateModified":"2014-04-02","changeDescription":"04/01/14 jc released UMLLOADER_CAP content per R. Crowley.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}